<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04999449</url>
  </required_header>
  <id_info>
    <org_study_id>STUDY02001115</org_study_id>
    <nct_id>NCT04999449</nct_id>
  </id_info>
  <brief_title>Nebulizer Delivery of Intranasal Scopolamine</brief_title>
  <official_title>Nebulizer Delivery of Intranasal Scopolamine</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dartmouth-Hitchcock Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dartmouth-Hitchcock Medical Center</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      To develop a better way to administer anti-motion sickness medications using an intranasal&#xD;
      nebulizer.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">August 2022</start_date>
  <completion_date type="Anticipated">August 2026</completion_date>
  <primary_completion_date type="Anticipated">August 2026</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Pharmacokinetic study followed by double-blind, placebo-controlled, dose-ranging design</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to maximal concentration for scopolamine after intranasal administration (Tmax)</measure>
    <time_frame>Baseline, 180 minutes</time_frame>
    <description>Plasma scopolamine concentrations will be measured using an liquid chromatography-mass spectrometry (LC- MS) assay. Tmax is measured in minutes to reach the maximum concentration.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Side effects of intranasal scopolamine, as measured through a questionnaire with a subjective rating scale</measure>
    <time_frame>180 minutes</time_frame>
    <description>A questionnaire will be administered asking about the participant's side effect profile after taking intranasal scopolamine. The questionnaire will have a subjective rating scale of 0-10 on the potential scopolamine side effects expected</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Effectiveness in reducing motion sickness as measured by duration of chair ride.</measure>
    <time_frame>Baseline, end of chair ride (maximum of 20 minutes)</time_frame>
    <description>The degree of motion sickness will be assessed by measuring the total number of minutes the subject rides in the chair before stopping</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Scopolamine</condition>
  <condition>Motion Sickness</condition>
  <arm_group>
    <arm_group_label>Pharmacokinetic</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive 1 dose of Scopolamine 0.4 mg delivered via a intranasal nebulizer developed by Creare LLC.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Chair</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive 1 dose of Scopolamine 0.2 mg, 1 dose of Scopolamine 0.4 mg, and 1 dose of placebo saline delivered via the Creare LLC intranasal nebulizer. These dosages are all 1 week apart and the order is randomized.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Scopolamine</intervention_name>
    <description>Intranasal scopolamine at 0.2 mg or 0.4 mg</description>
    <arm_group_label>Chair</arm_group_label>
    <arm_group_label>Pharmacokinetic</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Intranasal saline placebo</description>
    <arm_group_label>Chair</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female&#xD;
&#xD;
          -  Adults age 21-49&#xD;
&#xD;
          -  Normal weight for body size, based on BMI table&#xD;
&#xD;
          -  General good health, as determined by a verbally provided medical history&#xD;
&#xD;
          -  Normal brief neurological exam&#xD;
&#xD;
          -  Renal and hepatic function within normal ranges&#xD;
&#xD;
          -  Able to provide written informed consent to participate&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Drug allergies to scopolamine or other belladonna alkaloid&#xD;
&#xD;
          -  Use of medications within 1 week of starting the study&#xD;
&#xD;
          -  Use of an investigational drug within 30 days of starting the study&#xD;
&#xD;
          -  Tobacco smoking within the past year&#xD;
&#xD;
          -  Blood donation or significant blood loss within 30 days of starting the study&#xD;
&#xD;
          -  Significant gastrointestinal disorder (e.g. Crohn's Disease, ulcerative colitis,&#xD;
             chronic constipation), asthma, glaucoma, prostate problems, urinary obstruction, or&#xD;
             seizure disorders&#xD;
&#xD;
          -  History of alcohol or other drug abuse&#xD;
&#xD;
          -  Pregnancy or suspected pregnancy, or lactation (pregnancy will be confirmed with urine&#xD;
             pregnancy testing prior to drug administration)&#xD;
&#xD;
          -  Consumption of grapefruit juice within 7 days of scopolamine (SCOP) administration&#xD;
&#xD;
          -  Nasal, nasal sinus, or nasal mucosa surgery within 90 days prior to study initiation&#xD;
&#xD;
          -  Other significant surgeries within 90 days&#xD;
&#xD;
          -  Significant deviated septum that blocks air flow in one nostril&#xD;
&#xD;
          -  Rhinitis, sinus infection, severe allergies, and other upper respiratory infections&#xD;
             within 30 days prior to the study&#xD;
&#xD;
          -  Current use of an intranasal medication&#xD;
&#xD;
          -  Wheezing or other respiratory problem&#xD;
&#xD;
          -  Unable to consent&#xD;
&#xD;
          -  Prisoner&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>49 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jay C Buckey, Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dartmouth-Hitchcock Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Samantha M Leigh, BA</last_name>
    <phone>(603) 646-5327</phone>
    <email>samantha.m.leigh@dartmouth.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Abigail M Fellows</last_name>
    <phone>(603) 646-5333</phone>
    <email>abigail.m.fellows@dartmouth.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Dartmouth-Hitchcock Medical Center</name>
      <address>
        <city>Lebanon</city>
        <state>New Hampshire</state>
        <zip>03756</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>August 2, 2021</study_first_submitted>
  <study_first_submitted_qc>August 7, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 10, 2021</study_first_posted>
  <last_update_submitted>September 12, 2021</last_update_submitted>
  <last_update_submitted_qc>September 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Dartmouth-Hitchcock Medical Center</investigator_affiliation>
    <investigator_full_name>Jay C. Buckey Jr.</investigator_full_name>
    <investigator_title>Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>Scopolamine</keyword>
  <keyword>Motion Sickness</keyword>
  <keyword>Space Physiology</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Motion Sickness</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Scopolamine</mesh_term>
    <mesh_term>Butylscopolammonium Bromide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

